Shots:

• The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7)- South Africa (B.1.351)- and Japan/Brazil (B.1.128) variants
• The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs is underway
• The collaboration follows Sorrento’s efforts to eradicate COVID-19 which includes STI-2020 (COVI-AMG) and STI-2099 (COVIDROPS). The license contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized mAb for therapeutic applications

 ­ Ref: GlobeNewswire | Image: PRNewswire